SEC Form 4 · accession 0001181431-15-002912
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Kung
Director
Period of report
Feb 18, 2015
Accepted (ET)
Feb 20, 2015 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 18, 2015 | M | 930 | $0.00 | A | 35,582 | D | |
| Common StockF2 | holding | — | — | — | 7,799,737 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Feb 18, 2015 | M | 930 | D | — | — | Common Stock | 930 | 2,790 | D |
Explanation of responses
- F1Vesting of restricted stock units.
- F2The shares reported are held of record collectively by Vivo Ventures Fund V, L.P., Vivo Ventures V Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P. and Vivo Ventures VI Affiliates Fund, L.P. (the "Vivo Funds"). Dr. Kung is the managing partner of Vivo Ventures. As a result, Dr. Kung may be deemed the beneficial owner of the shares of common stock owned collectively by the Vivo Funds. Dr. Kung hereby disclaims any beneficial ownership of any shares directly held by the Vivo Funds, except to the extent of his pecuniary interest therein.
- F3Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
- F4The restricted stock units vest in four equal annual installments beginning on February 18, 2015. Vested shares will generally be delivered to the reporting person within 30 days following the vesting date.